Literature DB >> 17201845

Randomized study of propofol effect on electrophysiological properties of the atrioventricular node in patients with nodal reentrant tachycardia.

Paulo Warpechowski1, Gustavo G Lima, Cláudio M Medeiros, Ari Tadeu L Santos, Marcelo Kruse, Marcelo H Migloransa, Renato A K Kalil.   

Abstract

BACKGROUND: Atrioventricular nodal reentrant tachycardia (AVNRT) is probably the most common form of paroxysmal supraventricular tachycardia. Percutaneous catheter ablation is a technique to interrupt cardiac conduction pathways selectively. The anesthetist is challenged to provide a safe anesthetic which takes into account the electrophysiologist's requirements for minimal cardiac conduction interference. Propofol is an ideal drug. However, previous studies have shown that the infusion of propofol has sometimes been associated with bradyarrhythmias or conversion of arrhythmias to sinusal rhythm. The purpose of this report is to verify the interferences of propofol in the electrophysiological properties of the atrioventricular (AV) node conduction system in patients with AVNRT.
METHODS: Patients were randomly assigned to receive either a placebo or propofol at sedative doses. An electrophysiological study was performed consisting of measuring the anterograde (AERPFP) and retrograde effective refractory period of the fast (RERPFP) and the anterograde effective refractory period of the slow (AERPSP) AV nodal pathway. Reciprocating tachycardia was induced and the cycle length (CL) and atrial-His (AH), His-ventricular (HV), and ventriculoatrial (VA) intervals were measured.
RESULTS: Propofol did not cause alteration (P > 0.05) in the AERPFP or RERPFP and the AERPSP AV nodal pathway. The AH, HV, and VA intervals were not affected. Sustained reciprocating tachycardia could be induced in the all patients. All slow pathways were successfully identified and ablated.
CONCLUSION: Propofol has no effect on the electrophysiological properties of the AV node conduction system. It is thus a suitable anesthetic agent for use in patients undergoing ablative procedures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201845     DOI: 10.1111/j.1540-8159.2006.00550.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  4 in total

Review 1.  Propofol and arrhythmias: two sides of the coin.

Authors:  Qiang Liu; Ai-ling Kong; Rong Chen; Cheng Qian; Shao-wen Liu; Bao-gui Sun; Le-xin Wang; Long-sheng Song; Jiang Hong
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

2.  Atrial fibrillation organization: quantification of propofol effects.

Authors:  Raquel Cervigón; Javier Moreno; César Sánchez; Richard B Reilly; Julián Villacastín; José Millet; Francisco Castells
Journal:  Med Biol Eng Comput       Date:  2008-11-19       Impact factor: 2.602

3.  Outcomes of deep sedation for catheter ablation of paroxysmal supraventricular tachycardia, with adaptive servo ventilation.

Authors:  Tatsuya Hayashi; Akira Mizukami; Shunsuke Kuroda; Ryo Tateishi; Nozomu Kanehama; Shinichi Tachibana; Kazuto Hayasaka; Jiro Hiroki; Hirofumi Arai; Kenji Yoshioka; Ryota Iwatsuka; Daisuke Ueshima; Akihiko Matsumura; Masahiko Goya; Tetsuo Sasano
Journal:  J Arrhythm       Date:  2020-12-05

4.  Propofol suppresses the His-ventricular conduction in paediatric patients.

Authors:  Mayuka Matsushima; Seishi Kimura; Atsuhiro Kitaura; Shinichi Hamasaki; Tatsushige Iwamoto; Takashi Mino; Kenichi Masui; Shinichi Nakao
Journal:  J Clin Pharm Ther       Date:  2020-10-24       Impact factor: 2.512

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.